Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase ...
